Surgical Oncology Overview

Principles

Definition

Surgical oncology is a specialized field of academic medicine and research dedicated to the application of surgical principles for the diagnosis, treatment, and management of malignant neoplasms (cancers). This interdisciplinary field investigates the efficacy and optimization of surgical techniques for tumor excision, staging, and reconstruction, considering tumor biology and integration with other therapeutic modalities. Its significance lies in its foundational role in curative and palliative cancer care and its ongoing research into novel surgical approaches aimed at improving oncological outcomes, functional recovery, and patient quality of life.

Ontological type

Core Procedures

Multimodal Integration

Staging and Margins

Key developments

Key Figures

Biology-Guided Standardization era

Charles B. Wilson [1] is associated with University of California, San Francisco [3] and University of Washington [4] during the Biology-Guided Standardization era. His key contribution is the 1978 paper Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas [7], which helped establish adjuvant therapy roles and informed prognostication and operative decision-making in this era. M. S. Mahaley [2] is associated with University of Pittsburgh [5] and Duke University [6] during this era. His contribution, via the same 1978 paper [7], helped standardize the use of BCNU and radiotherapy in anaplastic gliomas, shaping prognostic frameworks and surgical guidelines for the era.

Evidence-Based Multimodality era

Jaap Verweij [1] is a prominent figure in the era of Evidence-Based Multimodality, collaborating with the Institute of Cancer Research [3] and the University of California, San Francisco [4]. His key contribution is the 2000 paper New Guidelines to Evaluate the Response to Treatment in Solid Tumors [6], which established standardized response criteria that enabled reproducible assessment and comparability across trials in this era. Elizabeth A. Eisenhauer [2] is associated with the Institute of Cancer Research [3] and Johns Hopkins University [5]. Her pivotal contribution centers on the New Guidelines to Evaluate the Response to Treatment in Solid Tumors [6], which advanced standardized response assessment and enabled cross-institution comparability, shaping evidence-based multimodality care across the Institute of Cancer Research [3] and Johns Hopkins University [5].

Molecular and Immunotherapy Era era

Bert Vogelstein [1] is a leading cancer biologist whose work during the Molecular and Immunotherapy Era was associated with Johns Hopkins University [3] and Baylor College of Medicine [4]. His key contributions in this era are exemplified by the PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [5] and Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [6], which established mismatch repair deficiency as a predictive biomarker for immunotherapy and reshaped perioperative planning. Kenneth W. Kinzler [2] is a foundational cancer genetics figure whose work during this era is associated with Johns Hopkins University [3] and Baylor College of Medicine [4]. His key contributions, as reflected in the same landmark papers PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [5] and Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [6], underscored how mismatch repair deficiency can predict immunotherapy responses and thus influence biomarker-driven surgical strategies in the era.